Inhibition of mTOR pathway attenuates migration and invasion of gallbladder cancer via EMT inhibition

被引:83
作者
Zong, Huajie [1 ]
Yin, Baobing [1 ]
Zhou, Huading [1 ]
Cai, Duan [1 ]
Ma, Baojin [1 ]
Xiang, Yang [1 ]
机构
[1] Fudan Univ, Dept Gen Surg, Huashan Hosp, Shanghai 200040, Peoples R China
关键词
Gallbladder cancer; mTOR; EMT; TGF-beta; EPITHELIAL-MESENCHYMAL TRANSITION; RAPAMYCIN; CARCINOMA; CHEMOTHERAPY; METASTASIS; PROGNOSIS; MOTILITY;
D O I
10.1007/s11033-014-3321-4
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Gallbladder cancer (GBC) is an aggressive disease in which epithelial-mesenchymal transition (EMT) plays a critical role. Whether inhibition of mTOR effects via EMT reversal in GBC remains unclear. Using genetic and pharmacologic inhibitions of mTOR, we investigated the changes of EMT levels in GBC cells. Expressions of EMT related genes were also studied. Migration and invasion assays were carried out and in vivo tumour metastasis mouse models were established. Circulating tumour DNA was quantified. We used EMT index (ratio of Vimentin/Ecadherin expression) to profile EMT levels. We found that inhibition of mTOR using shRNAs and rapamycin inhibited EMT in GBC-SD gallbladder cancer cells. Inhibition of mTOR inhibited EMT in GBC-SD cells in TGF-beta-dependent manner, which was contributed majorly by mTORC2 inhibition. Rapamycin decreased invasiveness and migration of GBC-SD cells in vitro and in vivo. We have in the current study shown that rapamycin diminishes the ability of invasion and migration of GBC via inhibition of TGF-beta-dependent EMT. Our findings contribute to the understanding of the carcinogenesis of GBC.
引用
收藏
页码:4507 / 4512
页数:6
相关论文
共 19 条
  • [1] Chemotherapy in gallbladder carcinoma
    Abahssain, Halima
    Afchain, Pauline
    Melas, Nawfal
    Ismaili, Nabil
    Rahali, Rabia
    Rabti, Hind M.
    Errihani, Hassan
    [J]. PRESSE MEDICALE, 2010, 39 (12): : 1238 - 1245
  • [2] de Aretxabala X, 2004, REV MED CHILE, V132, P51
  • [3] Laparoscopic cholecystectomy: Its effect on the prognosis of patients with gallbladder cancer
    de Aretxabala, XA
    Roa, IS
    Mora, JP
    Orellana, JJ
    Riedeman, JP
    Burgos, LA
    Silva, VP
    Cuadra, AJ
    Wanebo, HJ
    [J]. WORLD JOURNAL OF SURGERY, 2004, 28 (06) : 544 - 547
  • [4] deAretxabala XA, 1997, EUR J SURG, V163, P419
  • [5] Combination of Rapamycin, CI-1040, and 17-AAG Inhibits Metastatic Capacity of Prostate Cancer via Slug Inhibition
    Ding, Guanxiong
    Feng, Chenchen
    Jiang, Haowen
    Ding, Qiang
    Zhang, Limin
    Na, Rong
    Xu, Hua
    Liu, Jun
    [J]. PLOS ONE, 2013, 8 (10):
  • [6] Gallbladder cancer
    Gourgiotis, Stavros
    Kocher, Hemant M.
    Solaini, Leonardo
    Yarollahi, Arvin
    Tsiambas, Evangelos
    Salemis, Nikolaos S.
    [J]. AMERICAN JOURNAL OF SURGERY, 2008, 196 (02) : 252 - 264
  • [7] mTORC1 and mTORC2 Regulate EMT, Motility, and Metastasis of Colorectal Cancer via RhoA and Rac1 Signaling Pathways
    Gulhati, Pat
    Bowen, Kanika A.
    Liu, Jianyu
    Stevens, Payton D.
    Rychahou, Piotr G.
    Chen, Min
    Lee, Eun Y.
    Weiss, Heidi L.
    O'Connor, Kathleen L.
    Gao, Tianyan
    Evers, B. Mark
    [J]. CANCER RESEARCH, 2011, 71 (09) : 3246 - 3256
  • [8] Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive
    Jacinto, E
    Loewith, R
    Schmidt, A
    Lin, S
    Rüegg, MA
    Hall, A
    Hall, MN
    [J]. NATURE CELL BIOLOGY, 2004, 6 (11) : 1122 - U30
  • [9] The basics of epithelial-mesenchymal transition
    Kalluri, Raghu
    Weinberg, Robert A.
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2009, 119 (06) : 1420 - 1428
  • [10] TGF-β-induced activation of mTOR complex 2 drives epithelial-mesenchymal transition and cell invasion
    Lamouille, Samy
    Connolly, Erin
    Smyth, James W.
    Akhurst, Rosemary J.
    Derynck, Rik
    [J]. JOURNAL OF CELL SCIENCE, 2012, 125 (05) : 1259 - 1273